Introduction
============

As a common chronic disease that substantially burdens both patients' lives and health economics,[@b1-jaa-6-093],[@b2-jaa-6-093] asthma has 300 million sufferers worldwide, with an additional 100 million people estimated to be affected by 2025.[@b3-jaa-6-093] The number of patients diagnosed with asthma in Turkey was estimated at 3--4 million,[@b4-jaa-6-093] while the prevalence proportion was reported at 7.4% by the Global Initiative for Asthma (GINA) -- Global Burden of Asthma Report.[@b5-jaa-6-093]

Although the results of clinical trials suggest that asthma control can be reached in most patients,[@b6-jaa-6-093] the epidemiologic evidence suggests a low level of disease control in many countries including Turkey,[@b7-jaa-6-093]--[@b9-jaa-6-093] despite the availability of international and national asthma guidelines, and effective medications that would enable optimum control of the disease.[@b5-jaa-6-093],[@b10-jaa-6-093]

Therefore, the challenge to find the best way to assess asthma control and define management strategies to ensure that this control is achieved and maintained, still remains.[@b11-jaa-6-093] The update of the GINA 2006 guidelines recommends a newly introduced asthma management approach, based on the monitoring of disease control, to facilitate the acceptance and use of asthma guidelines in clinical practice.[@b5-jaa-6-093] This approach is based on the use of combined therapies in which inhaled corticosteroids (ICS) are given, mainly in combination with long-acting beta-2-adrenoceptor agonists (LABA).[@b12-jaa-6-093]--[@b14-jaa-6-093] However, despite this availability of new pharmacological options and novel combinations of existing drug therapies, suboptimal asthma control rates are persistently high. [@b15-jaa-6-093]

In order to tackle this, early identification of the clinical and behavioral factors responsible for poor asthma control,[@b16-jaa-6-093] and interventions during routine outpatient visits for improving asthma trigger management,[@b17-jaa-6-093] have been recommended. In addition, follow-up consultations including checking the patients' adherence to their medication plan, and measures to reduce the exposure to risk factors have also been strongly recommended.[@b18-jaa-6-093]

Clinicians and general practitioners must be aware of the levels and determinants of asthma control in order to reflect and improve on the implementation of the asthma guidelines.[@b5-jaa-6-093],[@b19-jaa-6-093] Therefore this real-life prospective ASIT (Asthma Inhaler Treatment) study, conducted at 31 secondary and tertiary centers across Turkey, was designed to evaluate the profiles of persistent-asthma patients and their inhaler treatment devices in relation to asthma control, through a series of follow-ups.

Material and Methods
====================

Study population
----------------

A total of 572 patients with persistent asthma were included in this multi-center, non-interventional, single arm prospective observational study, conducted at 31 pneumology outpatient clinics across Turkey. The study was based on four consecutive visits, the first performed at the study enrolment (month 0, visit 1), and then follow-ups at 1,3, and 6 months. Female or male outpatients older than 18 years and diagnosed with persistent asthma according to the GINA criteria[@b12-jaa-6-093] at least 6 months previously, and who had received at least one dose of ICS + LABA either in separate or fixed combinations irrespective of pharmacological agent(s), were included. The exclusion criteria were: confirmed or suspected pregnancy; breastfeeding; comorbid COPD; allergy/sensitivity or intolerance to any kind of asthma treatment; anti-immunoglobulin E treatment within the last 4 months; treatment with leukotriene receptor antagonists; hospitalization due to symptomatic respiratory infection of asthma within the last 8 weeks; chronic diseases that were likely to negatively affect the prognosis (eg, carcinoma); chronic alcohol consumption; and substance abuse.

Following detailed explanation of the objectives and protocol of the study, written informed consent was obtained from each subject. The study was conducted in accordance with the ethical principles stated in the "Declaration of Helsinki" and approved by the Kocaeli University Research Ethics Committee.

Data collection
---------------

After certifying the patients' eligibility against the inclusion/exclusion criteria, data on sociodemographic characteristics (age, gender, educational status, and occupation), vital signs, physical examination findings, medical history, comorbid disorders, concomitant treatments, characteristics and clinical course of asthma disease, asthma control, and asthma treatment via inhaler device were collected at the initial enrollment visit. At each follow up visit, patients were evaluated for vital signs, physical examination findings, concomitant treatments, characteristics and clinical course of asthma disease, asthma control, and asthma treatment via inhaler device.

The Asthma Control Test (ACT), a standard test developed for reflecting the patient's perspective of his/her disease,[@b20-jaa-6-093] helps determine asthma control levels, predict exacerbations, and optimize therapy for the patients.[@b21-jaa-6-093],[@b22-jaa-6-093] The ACT^™^ has been translated into Turkish and cultural adaptation has been completed.[@b23-jaa-6-093]

In the present study, the ACT™ filled in by patients was used to assess their level of asthma control in the 4 weeks preceding the enrollment, considering an overall score of 20 or higher as controlled asthma, and a score less than 20 as uncontrolled asthma.

Statistical analysis
--------------------

Sample size was calculated to include at least 1050 patients to be able to observe 40% of the difference between two different treatment alternatives or inhaler devices and standard error of 2%, confidence level of \>95%, and statistical power of 90%. However, only 572 patients were enrolled in the study.

Stata Data Analysis and Statistical Software (Version 10, StataCorp LP, College Station, TX, USA) was used for statistical analysis. Data were expressed as "mean (standard deviation \[SD\])", percent (%) and 95% confidence interval where appropriate. Significance levels during the categorical comparison of the groups were evaluated by the Chi-square test using cross table statistics. The Kruskal--Wallis and Mann--Whitney U tests were used for independent groups without normal distribution, while Student's *t*-test was used for comparison of two independent groups. The ANOVA test and post-hoc Tukey's HSD test were used for more than two independent groups with normal distribution. Logistic regression analysis was performed with asthma control (categorical) as the dependent variable while "Enter" was selected as the method and "simple first" as the categorical variable coding scheme. Predictors with possible influence on dependent variable were added as covariates. All tests were two-sided and *P* \< 0.05 was considered statistically significant.

Results
=======

Baseline demographic, clinical and asthma-related characteristics
-----------------------------------------------------------------

The mean (SD) age of the 572 patients in the ASIT study was 42.7 (12.1) years and 76% (n = 435) were females. The majority of the patients (n = 440; 76.9%) were secondary school graduates and 61.9% were unemployed (55.8% housewives) ([Table 1](#t1-jaa-6-093){ref-type="table"}). Mean (SD) time from asthma onset was 8.0 (8.3) years while less than or equal to 5 years in 53.3% of the patients ([Table 1](#t1-jaa-6-093){ref-type="table"}). Active smokers represented 18.2% (n = 104) of the patients ([Table 1](#t1-jaa-6-093){ref-type="table"}).

Among the 530 patients with comorbidities, 56.1% (n = 321) had asthma-related disorders, and a single asthma-related comorbidity was noted in 67.9% of the patients ([Table 1](#t1-jaa-6-093){ref-type="table"}).

The evaluation of vital signs showed mean (SD) systolic blood pressure (BP) as 121.1 (15.6) mmHg, diastolic BP as 75.6 (8.9) mmHg, pulse as 81.2 (8.9)/min, and respiratory rate as 16.8 (3.2)/min. Mean (SD) body mass index (BMI) was 28.0 (5.4) (kg/m^2^).

Baseline characteristics associated with asthma control status
--------------------------------------------------------------

Overall, asthma was determined to be controlled in 61.5% (n = 352) of the patients, with no statistical difference in control level with respect to mean age, gender, asthma duration, educational, or employment status. The uncontrolled asthma group had a significantly higher number of active smokers (23.2%) versus 15.1% in the controlled asthma group (*P* = 0.015) ([Table 1](#t1-jaa-6-093){ref-type="table"}).

The presence of asthma-related comorbidities had significantly negative effects on asthma control ([Table 1](#t1-jaa-6-093){ref-type="table"}). Half (51.4%) of the patients with controlled asthma had asthma-related comorbidities, while this percentage rose to 63.6% (140/220) in the uncontrolled asthma group (*P* = 0.004). The most common asthma-related comorbidity was rhinitis, and this was significantly more frequent among uncontrolled asthma group (*P* = 0.009).

Asthma control status throughout the study visits
-------------------------------------------------

Overall, the ratio of patients with controlled asthma was significantly higher (61.5% at visit 1, 82.0% at visit 2, 84.8% at visit 3 and 87.3% at visit 4; *P* \< 0.001 for each) than that of uncontrolled asthma at each study visit and there was a significant progressive decrease in the ratio of uncontrolled patients at the follow-up visits compared to baseline (*P* \< 0.001 for each) from 38.5% to 12.7% at the end of the study ([Figure 1](#f1-jaa-6-093){ref-type="fig"}).

Asthma control status from visit 1 to visit 4: asthma duration, BMI, smoking status and comorbid disorders
----------------------------------------------------------------------------------------------------------

When asthma control status from visit 1 to visit 4 was evaluated in terms of time from asthma onset (0--15 versus more than 15 years), BMI (30 kg/m^2^ or higher versus less than 30 kg/m^2^), and smoking status (smoker versus non-smoker), a significant decrease in the ratio of patients with uncontrolled asthma was found in each case, regardless of the grouping ([Table 2](#t2-jaa-6-093){ref-type="table"}). Significantly higher rates of asthma control at visit 4 compared to visit 1 were detected even in patients with time from asthma onset more than 15 years ([Table 2](#t2-jaa-6-093){ref-type="table"}). On the other hand, the asthma control rate was significantly higher at all visits, both among nonsmokers compared to active smokers (64% versus 51%, *P* = 0.010 and 89% versus 78%; *P* = 0.030, respectively); and among patients with BMI lower than 30 kg/m^2^ compared to those with BMI 30 kg/m^2^ or higher at visit 4 (88.5% versus 81.8%, *P* = 0.009) ([Table 2](#t2-jaa-6-093){ref-type="table"}).

Patients with one (*P* \< 0.001), two (*P* = 0.004) and three (*P* = 0.021) comorbidities had significantly higher ACT scores at visit 4 compared to visit 1, while baseline ACT scores of patients with three comorbidities were significantly lower than baseline scores of patients with a single comorbidity (*P* = 0.007) ([Table 2](#t2-jaa-6-093){ref-type="table"}).

Asthma control status from visit 1 to visit 4: inhaler treatment
----------------------------------------------------------------

Significant improvement in asthma control status during follow-up was observed in patients using fixed dose ICS/LABA combination inhalers ([Table 3](#t3-jaa-6-093){ref-type="table"}). There was a significant decrease in the ratio of patients with uncontrolled asthma from visit 1 to visit 4 for patients who received: 'fluticasone propionate/salmeterol discus' (38.2% versus 11.4%, *P* \< 0.001); 'extra fine beclomethasone/formoterol solution spray' (32.7% versus 10.0%, *P* \< 0.001); and 'budesonide/formoterol turbuhaler' (41.7% to 14.9%, *P* \< 0.001). There were no significant changes in the ratio of uncontrolled asthma observed in patients receiving 'budesonide and formoterol aerolizer' (42.9% to 23.5%, *P* = 0.131) ([Table 3](#t3-jaa-6-093){ref-type="table"}). Overall, the ratio of patients with uncontrolled asthma was decreased by 45.2%--70.2%, depending on the inhaler type ([Figure 2](#f2-jaa-6-093){ref-type="fig"}).

Logistic regression analysis for predictors of asthma control
-------------------------------------------------------------

Using asthma control (categorical) as the dependent variable, logistic regression analysis showed that the presence of asthma-related comorbidity (odds ratio \[OR\], 0.602; 95% CI, 0.419;0.863, *P* = 0.006) and active smoking (OR, 0.522; 95% CI, 0.330; 0.825, *P* = 0.005) were significant predictors of asthma control ([Table 4](#t4-jaa-6-093){ref-type="table"}).

Discussion
==========

The principal findings of this real-life prospective ASIT study showed that the asthma control rate increased during follow up in adult outpatients with persistent asthma, moving from 61.5% to 87.0% after 6 months, regardless of patient demographics, smoking, educational, or employment status. Notably, the incidence of comorbid diseases was associated with poor asthma control, while fixed dose combinations proved highly effective in asthma control.

Failure in asthma control has been reported in several studies, despite variations in selected populations and methodology,[@b19-jaa-6-093] while objectives for good control proposed by international reference guidelines are still far from being met.[@b7-jaa-6-093],[@b24-jaa-6-093]--[@b26-jaa-6-093] National and international asthma management guidelines recommend continuous, preventive rather than symptom-driven and crisis-oriented care.[@b27-jaa-6-093],[@b28-jaa-6-093] In this regard, justifying emphasis on asthma control versus asthma severity in the guidelines, our finding of asthma control (ACT score of ≥20) in 87.3% of patients promisingly highlights the role of patient monitoring via close follow up in the achievement of better asthma control.

The Asthma Insights and Reality in Europe (AIRE) Study, a multinational, population-based telephone survey, showed that 94.7% of all patients fail to achieve proper control of their disease.[@b24-jaa-6-093] The ASES Study, an office-based study conducted in Spain, confirmed that the percentage of patients at primary care and pneumologist office visits who reported suffering symptoms more than once a week was 24% and 32%, respectively.[@b29-jaa-6-093] In a population-based screening conducted in eleven European countries within the scope of European Respiratory Health Survey (ERCHS) II, overall asthma control rate was reported to be 32%, while the proportion of uncontrolled asthma in ICS users greatly varied by country, ranging from 20% (Iceland) to 67% (Italy).[@b19-jaa-6-093] Recently, a survey conducted in five European countries indicated that 50.4% of asthmatics had low levels of control;[@b30-jaa-6-093] this percentage increased to 56.6% in a more recent survey conducted in the same countries.[@b31-jaa-6-093]

A cross-sectional study of 1188 patients with asthma from 28 centers in Turkey indicated controlled asthma in 51.5% of the patients (ACT ≥ 20),[@b9-jaa-6-093] while the Asthma Insights and Reality in Turkey (AIRET) study,[@b8-jaa-6-093] consistent with other international AIR surveys, demonstrated achievement of guideline-based asthma control in only 1.3% of participants, despite the availability of effective therapies.

The inconsistency of data on asthma control has been associated with the varied implementations of the asthma treatment guidelines in different countries, different treatment regimens, and geographic variation in asthma severity.[@b19-jaa-6-093] Moreover, comparison of data from different studies is difficult due to different asthma control measures and data collection methods adopted. For example, the higher proportion of controlled patients in our study compared to the ECRHS II survey[@b19-jaa-6-093] may be linked to the fact that in the latter, asthma control was evaluated with the GINA guidelines composite measure, including lung function, whereas the former used ACT, which excludes lung function; therefore a higher rate of asthma control is to be expected.[@b15-jaa-6-093]

The combined effects of failure to comply with recommendations and poor patient adherence to treatment, along with low usage of preventive medicine and low expectations of treatment, can be considered as the leading causes of poor disease control.[@b32-jaa-6-093] Given the positive influence of close patient monitoring on asthma control rates in our study, we consider better implementation of asthma management guidelines and patient education to raise awareness and expectations as crucial to improving asthma outcomes in Turkey.[@b8-jaa-6-093]

The majority (79.5%) of patients with persistent asthma in our study were receiving fixed combination therapy. SABA was used in 32.5%, ICS in 20.3%, and LABA in 13.6% of patients, while spray (31.5%), turbuhaler (29.9%) and discus (26.6%) were the most frequently used inhaler types, with a high level (\>94%) of overall satisfaction from inhaler therapy. Likewise, data from a past study concerning determinants of asthma control at tertiary healthcare level in Turkey indicated use of ICS and LABA combination in 57% of the 900 patients surveyed.[@b9-jaa-6-093]

The use of fixed combination therapy in the majority of our patients is consistent with the remarkable alteration in practice patterns of asthma management in the last decade. There has been an increase in the prescription rate of controller medications, including multiple controllers for ICS + LABA, after Asthma Insights and Reality (AIR) surveys in the US, Europe, Asia-Pacific, Japan and Latin America populations reported low levels of asthma control.[@b24-jaa-6-093],[@b33-jaa-6-093]--[@b36-jaa-6-093]

Our findings found asthma control to be negatively associated with the incidence of comorbidities such as rhinitis, sinusitis and GERD, while it was positively associated with the use of fixed dose combination treatments. Significantly higher rates of asthma control were achieved by visit 4 compared to visit 1, even in patients with ≥15 years of asthma duration, and irrespective of age, gender, asthma duration, smoking status or BMI. However the presence of asthma-related comorbidity and active smoking were found to be significant predictors of worse asthma control.

ICS/LABA fixed combinations are reportedly the most commonly used anti-asthmatic medications[@b15-jaa-6-093] and the most effective treatment choice.[@b15-jaa-6-093],[@b32-jaa-6-093] Our findings confirmed this, with 61.5% of patients using fixed dose combination treatment achieving asthma control.

Indeed, the use of fixed dose combination therapy (ICS/LABA) was among the factors associated with optimal control of asthma in a study from France,[@b37-jaa-6-093] along with normal BMI, non-smoker status, age \<50 and good compliance. On the other hand, exacerbation, use of reliever medication, switch of therapy and smoking have been listed as the factors for poor control in a Swiss study.[@b38-jaa-6-093] In another study from France, lack of asthma control in 41.1% of 4362 patients with persistent asthma was associated with patient-related factors including smoking, poor compliance and critical errors in device manipulation.[@b39-jaa-6-093]

Our study is also in line with the international population-based ECRHS II Survey conducted in 11 countries,[@b19-jaa-6-093] which reported no differences based on gender or age in categories of asthma control.

Asthma-related comorbidities were identified in 56.1% of patients overall in our study population, with rhinitis in 38.3%, GERD in 18.5% and sinusitis in 18.4%. This is in accordance with the most common comorbidities reported in asthma, including rhinitis, sinusitis, GERD, obstructive sleep apnea, hormonal disorders and psychiatric disorders.[@b40-jaa-6-093] Our findings that higher scores of ACT and higher likelihood of asthma control were linked with a lesser number of comorbidities, support the evidence that various comorbid conditions such as rhino-sinusitis, GERD, psychological disturbances, and respiratory infections, are often observed in asthmatic patients[@b40-jaa-6-093] and will place greater burden on healthcare systems unless taken into consideration in asthma treatment.[@b41-jaa-6-093]

In accordance with the data[@b31-jaa-6-093] that indicate smoking is a critical factor in the risk of poor asthma control[@b42-jaa-6-093],[@b43-jaa-6-093] and impaired corticosteroid response,[@b44-jaa-6-093] there was a significantly lower percentage of smokers classified under the controlled asthma category at visit 1 (51.0% versus 64.0% non-smokers, *P* = 0.010) and visit 4 (78.0% versus 89% non-smokers, *P* = 0.030) in our study population.

Our study's greatest value is in being the first large-scale, detailed survey conducted across Turkey using a patient evaluation questionnaire. The limitations are the lack of data on asthma severity and also the high drop-out rate (46.0%) from visit 1 to visit 4.

Conclusion
==========

In conclusion, our findings in this real-life prospective ASIT study revealed an asthma control rate of 61.5% in adult outpatients with persistent asthma in Turkey, which increased upon each follow-up, regardless of the smoking, educational and employment status of the patients. Fixed dose combinations proved superior in the achievement of asthma control. However, poor asthma control was associated with the incidence of comorbid diseases. Our findings have provided valuable data on the positive role of regular monitoring in disease control. We therefore advocate regular patient monitoring and patient education to raise awareness and therapeutic expectations, in order to better implement asthma management guidelines and achieve better control of the disease.
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![Asthma control improvement between visits.\
**Note:** \**P* \< 0.001, compared to rate of controlled asthma at the same visit; ^+^*P* \< 0.001 compared to visit 1.\
**Abbreviation:** ACT, asthma control test.](jaa-6-093Fig1){#f1-jaa-6-093}

![Change in percentage of uncontrolled asthma patients (n = 220) with fixed dose and seperate combination inhaler treatments from visit 1 to visit 4.\
**Abbreviations:** FP/s, fluticasone propionate/salmeterol; BDP/F, beclomethasone/formoterol; B/F, budesonide/formoterol; B + F, budesonide + formoterol.](jaa-6-093Fig2){#f2-jaa-6-093}

###### 

Sociodemographic characteristics of patients according to asthma control at baseline

                                                          Overall (n = 572)   Asthma control status   *P* value     
  ------------------------------------------------------- ------------------- ----------------------- ------------- ---------
                                                          **Mean (SD)**                                             
  Age (year)                                              42.7 (12.2)         43.6 (12.1)             41.3 (12.2)   0.061
   Age categories (year)                                  **n (%)**                                                 
    18--40                                                252 (44.1)          144 (40.9)              108 (49.1)    0.055
    41--60                                                272 (47.6)          175 (49.7)              97 (44.1)     0.192
    \>60                                                  48 (8.4)            33 (9.4)                15 (6.8)      0.276
  Gender                                                  **n (%)**                                                 
   Male                                                   137 (24.0)          92 (26.1)               45 (20.5)     0.127
   Female                                                 435 (76.0)          260 (73.9)              175 (79.5)    0.127
                                                          **Mean (SD)**                                             
  Time from asthma onset (years)                          8.0 (8.3)           8.0 (8.3)               8.0 (8.2)     1.00
                                                          **n (%)**                                                 
   ≤5                                                     305 (53.3)          191 (54.3)              114 (51.8)    0.560
   \>5 to ≤ 10                                            118 (20.6)          68 (19.3)               50 (22.7)     0.328
   \> 10 to ≤15                                           59 (10.3)           36 (10.2)               23 (10.5)     0.909
   \>15                                                   90 (15.7)           57 (16.2)               33 (15.0)     0.701
  Comorbidities                                           **n (%)**                                                 
   None                                                   162 (28.3)          115 (32.7)              47 (21.4)     0.003
   Non-asthma related                                     209 (36.5)          126 (35.8)              83 (37.7)     0.646
   Asthma related                                         321 (56.1)          181 (51.4)              140 (63.6)    0.004
    Rhinitis[\*](#tfn1-jaa-6-093){ref-type="table-fn"}    219 (68.2)          120 (66.3)              99 (70.7)     0.009
    Sinusitis[\*](#tfn1-jaa-6-093){ref-type="table-fn"}   105 (32.7)          57 (31.5)               48 (34.3)     0.092
    GERD[\*](#tfn1-jaa-6-093){ref-type="table-fn"}        106 (33.0)          59 (32.6)               47 (33.6)     0.169
  Number of comorbidities                                 **n (%)**                                                 
   1 comorbidity                                          218 (67.9)          109 (31)                109 (62.5)    \<0.001
   2 comorbidities                                        69 (21.5)           35 (9.9)                34 (15.5)     0.045
   3 comorbidities                                        34 (10.6)           19 (5.4)                15 (6.8)      0.491
  Active smoking                                          104 (18.2)          53 (15.1)               51 (23.2)     0.015
  Educational status                                      **n (%)**                                                 
   Illiterate                                             28 (4.9)            14 (4.0)                14 (6.4)      0.197
   Secondary school                                       440 (76.9)          279 (79.3)              161 (73.2)    0.092
   University                                             104 (18.2)          59 (16.8)               48 (21.8)     0.139
  Employment status                                       **n (%)**                                                 
   Unemployed                                             354 (61.9)          223 (63.4)              131 (59.5)    0.350
   Employed                                               210 (36.7)          126 (35.8)              84 (38.2)     0.562
   Missing                                                8                   3                       5             

**Note:**

Percent of patients with asthma-related comorbidities.

**Abbreviation:** ACT, asthma control test; n, number; SD, standard deviation.

###### 

Change in asthma control status from Visit 1--Visit 4 in terms of asthma duration, BMI, smoking status, and comorbid disorders

                                                                            Asthma control status                                                                                                                                     
  ------------------------------------------------------------------------- -------------------------------------------------------- ------------ ---------------------------------------------------------- ------------ ----------- ---------
  All patients                                                              352 (61.5)                                               269 (87.3)   \<0.001                                                    220 (38.5)   39 (12.7)   \<0.001
  Time from asthma onset (years)[a](#tfn5-jaa-6-093){ref-type="table-fn"}                                                                                                                                                             
   0--15 years (V1: n = 482; V4: n = 251)                                   294 (61.0)                                               215 (86.0)   \<0.001                                                    187 (39.0)   35 (14.0)   \<0.001
   ≥15 years (V1: n = 90; V4: n = 57)                                       57 (63.0)                                                52 (91.0)    \<0.001                                                    33 (37.0)    4 (9.0)     \<0.001
  BMI (kg/m^2^)[b](#tfn6-jaa-6-093){ref-type="table-fn"}                                                                                                                                                                              
   ≥30 (V1: n = 180; V4: n = 88)                                            107 (59.4)                                               72 (81.8)    0.0003                                                     73 (40.6)    16 (18.2)   \<0.001
   \<30 (V1: n = 363; V4: n = 131)                                          226 (62.3)                                               116 (88.5)   \<0.001                                                    137 (37.7)   15 (11.5)   \<0.001
  Smoking[c](#tfn7-jaa-6-093){ref-type="table-fn"}                                                                                                                                                                                    
   Smoker (V1: n = 104; V4: n = 50)                                         52 (51.0)                                                39 (78.0)    0.0014                                                     51 (49.0)    11 (22.0)   0.001
   Non-smoker (V1: n = 468; V4: n = 258)                                    300 (64.0)                                               230 (89.0)   \<0.001                                                    168 (36.0)   28 (11.0)   \<0.001
  **Comorbid disorder \#**                                                  **ACT score**                                                         ***P*value[\*\*](#tfn4-jaa-6-093){ref-type="table-fn"}**                            
  **Visit 1 Mean (SD)**                                                     **Visit 4 Mean (SD)**                                                                                                                                     
                                                                                                                                                                                                                                      
  1 (V1: n = 218; V4: n = 117)                                              19.9 (4.4)                                                            22.6 (3.3)                                                              \<0.001     
  2 (V1: n = 69; V4: n = 33)                                                19.3 (4.7)                                                            22.0 (4.1)                                                              0.004       
  3 (V1: n = 34; V4: n = 20)                                                16.9 (6.1)[\*\*](#tfn4-jaa-6-093){ref-type="table-fn"}                20.4 (4.6)                                                              0.021       

**Notes:**

Versus visit 1.

P = 0.007, compared to patients with 1 comorbid disorder. Comparison of asthma control rate:

time from asthma onset of 0--15 years versus ≥15 years at visit 1: *P* = 0.692; and at visit 4: *P* = 0.1643.

BMI of ≥30 kg/m^2^ versus \<30 kg/m^2^ at visit 1: *P* = 0.526; and at visit 4: *P* = 0.009.

smokers versus non-smokers at visit 1: *P* = 0.010; and at visit 4: *P* = 0.030.

**Abbreviations:** ACT, asthma control test; BMI, body mass index; n, number; SD, standard deviation; V, visits.

###### 

Asthma control level according to inhaler device as assessed by the physicians

                                                                  Total (n = 572)   Visit 1 (Month 0)   Total (n = 308)   Visit 4 (Month 6)   *P* value[\*](#tfn9-jaa-6-093){ref-type="table-fn"}               
  --------------------------------------------------------------- ----------------- ------------------- ----------------- ------------------- ----------------------------------------------------- ----------- -----------------------------------------------
  **According to inhaler types used**                                                                                                                                                                           
  Fixed dose combinations                                         **n (%)**                                                                                                                                     
   FP/S Discus                                                    152 (26.6)        94 (61.8)           58 (38.2)         79 (25.6)           70 (88.6)                                             9 (11.4)    \<0.001
    BDP/F Solution spray                                          107 (18.7)        72 (67.3)           35 (32.7)         60 (19.5)           54 (90.0)                                             6 (10.0)    \<0.001
   B/F Turbuhaler                                                 156 (27.3)        91 (58.3)           65 (41.7)         87 (28.2)           74 (85.1)                                             13 (14.9)   \<0.001
  Separate combinations                                           **n (%)**                                                                                                                                     
   B + F Aerolizer                                                84 (14.7)         48 (57.1)           36 (42.9)         51 (16.6)           39 (76.5)                                             12 (23.5)   0.131
   B + F Easyhaler[\*\*](#tfn10-jaa-6-093){ref-type="table-fn"}   21 (3.8)          14 (66.7)           7 (33.3)          8 (2.6)             8 (100.0)                                             0 (0.0)     [\*\*](#tfn10-jaa-6-093){ref-type="table-fn"}

**Notes:**

Rate of uncontrolled asthma visit 1 versus visit 4.

No statistical analysis was done because of small number of patients.

**Abbreviations:** ACT, asthma control test; B, budesonide; BDP, beclometasone dipropionate; F, formoterol; FP, fluticasone propionate; S, salmeterol; n,number.

###### 

Logistic regression analysis for predictors of asthma control

                                         OR      95% CI         *P* value
  -------------------------------------- ------- -------------- -----------
  Female                                 1.351   0.876; 2.085   0.173
  Asthma related comorbidity present     0.602   0.419; 0.863   0.006
  Asthma unrelated comorbidity present   0.926   0.624; 1.373   0.700
  Smoking                                0.522   0.330; 0.825   0.005
  Patient age \>60 years                 1.456   0.735; 2.883   0.281
  BMI ≥ 30 kg/m^2^                       0.926   0.628; 1.367   0.700
  Disease duration ≥10 years             1.070   0.710; 1.612   0.748
  Educated (literate)                    0.533   0.229; 1.238   0.143

**Abbreviations:** BMI, body mass index; CI, confidence interval; OR, odds ratio.
